Haleon Plc - ADR [HLN] vs United Therapeutics [UTHR] Detailed Stock Comparison

Haleon Plc - ADR

NYSE
Loading...

United Therapeutics Corporation

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Haleon Plc - ADR wins in 7 metrics, United Therapeutics Corporation wins in 13 metrics, with 0 ties. United Therapeutics Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Haleon Plc - ADR United Therapeutics Corporation Better
P/E Ratio (TTM) 18.72 20.60 Haleon Plc - ADR
Price-to-Book Ratio 1.88 3.53 Haleon Plc - ADR
Debt-to-Equity Ratio 52.37 0.53 United Therapeutics Corporation
PEG Ratio 15.42 0.83 United Therapeutics Corporation
EV/EBITDA 33.08 13.90 United Therapeutics Corporation
Profit Margin (TTM) 15.11% 41.94% United Therapeutics Corporation
Operating Margin (TTM) 23.17% 45.23% United Therapeutics Corporation
EBITDA Margin (TTM) 23.17% 45.23% United Therapeutics Corporation
Return on Equity 10.27% 19.72% United Therapeutics Corporation
Return on Assets (TTM) 4.67% 12.44% United Therapeutics Corporation
Free Cash Flow (TTM) $2.22B $1.04B Haleon Plc - ADR
Dividend Yield 1.63% N/A N/A
1-Year Return -16.01% 92.68% United Therapeutics Corporation
Price-to-Sales Ratio (TTM) 3.78 7.91 Haleon Plc - ADR
Enterprise Value $122.54B $22.28B Haleon Plc - ADR
EV/Revenue Ratio 8.23 7.00 United Therapeutics Corporation
Gross Profit Margin (TTM) 55.38% 86.91% United Therapeutics Corporation
Revenue per Share (TTM) $2 $72 United Therapeutics Corporation
Earnings per Share (Diluted) $0.50 $27.88 United Therapeutics Corporation
Beta (Stock Volatility) 0.33 0.75 Haleon Plc - ADR
Short % of Float 0.43% 8.58% Haleon Plc - ADR

Haleon Plc - ADR vs United Therapeutics Corporation Stock Performance Analysis

Loading Price Chart...

HLN
UTHR

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Haleon Plc - ADR-0.66%2.02%1.23%-13.29%-7.73%-9.30%
United Therapeutics Corporation0.66%0.90%-3.34%2.86%9.85%10.64%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Haleon Plc - ADR-16.01%8.43%23.21%23.21%23.21%23.21%
United Therapeutics Corporation92.68%137.11%205.88%434.68%903.79%2,026.01%

Performance & Financial Health Analysis: Haleon Plc - ADR vs United Therapeutics Corporation

MetricHLNUTHR
Market Information
Market Cap i$42.40B$25.11B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i6,594,249464,464
90 Day Avg. Volume i7,985,230635,891
Last Close$9.07$549.57
52 Week Range$8.65 - $11.28$272.12 - $609.35
% from 52W High-19.59%-9.81%
All-Time High$11.42 (Jun 02, 2025)$609.35 (May 06, 2026)
% from All-Time High-20.58%-9.81%
Growth Metrics
Quarterly Revenue Growth0.01%0.07%
Quarterly Earnings Growth0.86%0.21%
Financial Health
Profit Margin (TTM) i0.15%0.42%
Operating Margin (TTM) i0.23%0.45%
Return on Equity (TTM) i0.10%0.20%
Debt to Equity (MRQ) i52.370.53
Cash & Liquidity
Book Value per Share (MRQ)$4.99$162.60
Cash per Share (MRQ)$0.15$66.63
Operating Cash Flow (TTM) i$3.56B$1.56B
Levered Free Cash Flow (TTM) i$1.89B$583.20M
Dividends
Last 12-Month Dividend Yield i1.63%N/A
Last 12-Month Dividend i$0.17N/A

Valuation & Enterprise Metrics Analysis: Haleon Plc - ADR vs United Therapeutics Corporation

MetricHLN (Apr 24, 2026)UTHR (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i18.7220.60
Forward P/E i15.4216.87
PEG Ratio i15.420.83
Price to Sales (TTM) i3.787.91
Price to Book (MRQ) i1.883.53
Market Capitalization
Market Capitalization i$42.40B$25.11B
Enterprise Value i$122.54B$22.28B
Enterprise Value Metrics
Enterprise to Revenue i8.237.00
Enterprise to EBITDA i33.0813.90
Risk & Other Metrics
Beta i0.330.75
Book Value per Share (MRQ) i$4.99$162.60

Financial Statements Comparison: Haleon Plc - ADR vs United Therapeutics Corporation

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricHLN (2025)UTHR (2025)
Revenue/Sales i11.03B3.18B
Cost of Goods Sold i3.95B384.40M
COGS % of Revenue i35.8%12.1%
Gross Profit i7.08B2.80B
Gross Margin i64.2%87.9%
Research & Development i316.00M550.00M
Operating Income (EBIT) i2.41B1.52B
Operating Margin i21.9%47.7%
EBITDA i2.81B1.84B
EBITDA Margin i25.5%57.9%
Pre-Tax Income i2.15B1.71B
Pre-Tax Income % of Revenue i19.5%53.9%
Income Tax i472.00M379.20M
Income Tax % of Revenue i4.3%11.9%
Net Income (Profit) i1.68B1.33B
Profit Margin i15.2%41.9%

Balance Sheet & Liquidity Metrics

MetricHLN (2025)UTHR (2025)
Cash & Equivalents i1.26B1.56B
Total Current Assets i4.55B3.70B
Total Current Assets % of Revenue i41.3%116.3%
Total Current Liabilities i4.93B560.60M
Total Current Liabilities % of Revenue i44.7%17.6%
Long-Term Debt i7.75BN/A
Long-Term Debt % of Revenue i70.2%0.0%
Total Shareholders Equity i16.48B7.10B
Retained Earnings i27.85B8.56B
Retained Earnings % of Revenue i252.5%268.9%
Property, Plant & Equipment i1.00M0

Cash Flow Statement Comparison

MetricHLN (2025)UTHR (2025)
Operating Cash Flow i2.19B1.44B
Operating Cash Flow % of Revenue i19.8%45.3%
Capital Expenditures i-322.00M-520.50M
Free Cash Flow i2.22B1.04B
FCF Margin i20.1%32.5%
Debt Repayment i-1.35B-500.00M
Common Stock Repurchase i-654.00M-1.02B

Short Interest & Institutional Ownership Analysis

MetricHLNUTHR
Shares Short i19.28M2.84M
Short Ratio i2.144.40
Short % of Float i0.43%8.58%
Shares Outstanding i8.91B43.64M
Float Shares i8.86B40.32M
% Held by Insiders i0.01%1.94%
% Held by Institutions i12.74%97.78%
% Held by Public i87.25%0.28%

Dividend Analysis & Yield Comparison: Haleon Plc - ADR vs United Therapeutics Corporation

MetricHLNUTHR
Last 12-Month Dividend i$0.17N/A
Last 12-Month Dividend Yield i1.63%N/A
3-Year Avg Annual Dividend i$0.11N/A
3-Year Avg Dividend Yield i0.91%N/A
3-Year Total Dividends i$0.34N/A
Ex-Dividend DateApr 25, 2025N/A